4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
March 2010 in “Ejc Supplements” CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
January 2017 in “Journal of Antivirals & Antiretrovirals” Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
17 citations
,
January 2014 in “Stem Cells Translational Medicine” Canine epidermal neural crest stem cells could be a promising treatment for spinal cord injuries in dogs.
May 2022 in “Голова и шея.” Exosomes show promise for targeted treatment of HER2-positive breast cancer.
July 2025 in “Scientific Reports” Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
108 citations
,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
13 citations
,
November 2021 in “Frontiers in Molecular Biosciences” Reducing reactive oxygen species can help treat nerve damage from platinum cancer drugs.
12 citations
,
February 2019 in “Journal of patient-reported outcomes” Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
4 citations
,
November 2022 in “BMC Women s Health” HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
1 citations
,
May 2022 in “Голова и шея.” p53 protein may help protect or kill neurons under stress.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
222 citations
,
October 2014 in “Annual Review of Pharmacology and Toxicology” Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.
5 citations
,
January 2022 in “Proceedings of the Pakistan Academy of Sciences B Life and Environmental Sciences” Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.